用多分子标记物预测新辅助化疗疗效

王坤; 吴一龙; 郑登云; 廖宁; 祖健; 李学瑞; 林雪挺

doi:10.3971/j.issn.1000-8578.2039

用多分子标记物预测新辅助化疗疗效

广东省人民医院肿瘤中心乳腺科; 广东省人民医院肿瘤中心乳腺科 510080广州; 510080广州

详细信息

通讯作者:
吴一龙

中图分类号: R737. 9 ;R730. 53
计量
- 文章访问数: 1967
- HTML全文浏览量: 21
- PDF下载量: 649
出版历程
- 收稿日期: 2007-02-16
- 修回日期: 2007-06-10
- 刊出日期: 2008-03-04

Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients by Using Molecular Markers

Department of Breast Cancer; Cancer Center; Guangdong Provincial People s Hospital; Guangzhou 510080; China

More Information

Corresponding author:
WU Yi-long: WU Yilong

摘要

摘要: 目的探讨ER、PR、C-erbB-2和P53与乳腺癌新辅助化疗疗效的相关性。方法局部晚期乳腺癌患者接受EC或TP方案化疗，化疗前空芯针穿刺活检，采用免疫组化法检测肿瘤组织的ER、PR、C-erbB-2和P53的表达情况。结果22例新辅助化疗RR达81．8％，其中CR5例（22．7％），pCR4例（18．2％），PR13例（59．1%），SD4例（18．2％）。研究发现ER、PR和C-erbB-2表达在3组间有显著性差异，但与新辅助化疗的疗效无关联性。结论ER、PR和C-erbB-2的表达在不同疗效组有差异，但目前不能预测新辅助化疗的疗效。
- 乳腺肿瘤 /
- 预测 /
- 新辅助化疗
Abstract: Objective 　To investigate the expression and correlation of ER、PR、C2erbB22 and P53 with the response of neoadjuvant chemotherapy. Methods 　The local advanced breast cancer patient s were under2 went core needle biop sy before they were given neoadjuvant chemotherapy of EC or TP. Expression of ER、PR、C2erbB22 and P53 were tested in 22 cases by immunohistochemical methods. Results 　The re2 sponse rate was 81. 8 %, including CR 22. 7 % and PR 59. 1 %, and the SD is 18. 2 %。There was a statit2 ical significance between expression of ER、PR 、C2erbB22 and the response to neoadjuvant chemotherapy. But there was no correlation between expression of ER、PR 、C2erbB22 and the response to neoadjuvant chemotherapy. Conclusion 　There is a significant difference between expression of ER、PR 、C2erbB22 and the response to neoadjuvant chemotherapy, but we can't predict the response of neoadjuvant chemothera2 py. We need to do more research to separtate the CR and SD.
- Breast neoplasm /
- Predict /
- Neoadjuvant chemotherapy